BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck at the 2024 European Society for Medical Oncology Annual Meeting
| BCAB Stock | USD 0.39 0.01 2.63% |
About 72 percent of all Bioatla's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Bioatla suggests that quite a large number of traders are confidant. The current market sentiment, together with Bioatla's historical and current headlines, can help investors time the market. In addition, many technical investors use Bioatla stock news signals to limit their universe of possible portfolio assets.
An ongoing complete response with an overall response rate of 32 percent achieved across two dosing regimens Underscores ozuriftamab vedotins activity in a high unmet need SCCHN patient population The conditionally binding ADC targeting ROR2 was notably well tolerated The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024 SAN DIEGO, Sept. 16, 2024 -- BioAtla, Inc. , a global clinical-stage biotechnology company fo
Read at finance.yahoo.com
 |
Bioatla Fundamental Analysis
We analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Bioatla is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Bioatla Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bioatla stock to make a market-neutral strategy. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics with similar companies.
Peers
Bioatla Related Equities
| ERAS | Erasca | 31.82 | ||||
| PASG | Passage Bio | 25.00 | ||||
| NAUT | Nautilus Biotechnology | 8.11 | ||||
| ADAG | Adagene | 5.95 | ||||
| RZLT | Rezolute | 5.32 | ||||
| GLUE | Monte Rosa | 4.19 | ||||
| NRIX | Nurix Therapeutics | 2.76 | ||||
| IKNA | Ikena Oncology | 2.61 | ||||
| KYMR | Kymera Therapeutics | 2.35 | ||||
| FHTX | Foghorn Therapeutics | 0.47 | ||||
| DSGN | Design Therapeutics | 0.25 | ||||
| PMVP | Pmv Pharmaceuticals | 1.10 | ||||
| IPSC | Century Therapeutics | 1.75 | ||||
| ANTX | AN2 Therapeutics | 2.54 | ||||
| CCCC | C4 Therapeutics | 3.08 | ||||
| OLMA | Olema Pharmaceuticals | 3.69 | ||||
| ACRV | Acrivon Therapeutics, | 5.98 | ||||
| STTK | Shattuck Labs | 9.57 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |